# Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)

Source: https://onco.cc/trials/nct04238637/  
OnCo record `nct04238637` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of durvalumab and tremelimumab in gallbladder cancer and other biliary tract cancers, run by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, active and no longer recruiting.

## Summary

Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC) is a phase 2, randomised interventional study registered as NCT04238637 by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, with a registry enrolment figure of 50 participants, started 2019-11-01 and due to reach its primary completion in 2026-08. Interventions recorded: Durvalumab, Tremelimumab. Conditions listed: Intrahepatic Cholangiocarcinoma. Sites: Germany. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-24
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT04238637
- Phase: 2
- Setting: Phase II Study of Immunotherapy With Durvalumab (MEDI4736) or Durvalumab and Tremelimumab, Both Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)
- Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT04238637: https://clinicaltrials.gov/study/NCT04238637

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/), [Intrahepatic cholangiocarcinoma](https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/), [Tremelimumab](https://onco.cc/drugs/tremelimumab/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct04238637.json